PTU - Polskie Towarzystwo Urologiczne
list of articles:

Surprisingly positive effect of palliative immunochemotherapy of lung- and liver-disseminated renal cancer
Article published in Urologia Polska 2005/58/2.


Grzegorz Świątoniowski 1, Szymon Brużewicz 2, Tomasz Kłaniewski 1, Elżbieta Suder 3, Włodzimierz Molenda 1
1 Klinika Chorób Wewnętrznych 4. Wojskowego Szpitala Klinicznego z Polikliniką we Wrocławiu
Kierownik kliniki: płk dr hab. med. Włodzimierz Molenda
2 Katedra i Zakład Higieny Akademii Medycznej we Wrocławiu
Kierownik: dr hab. Krystyna Pawlas
3 Katedra i Zakład Anatomii Prawidłowej Akademii Medycznej we Wrocławiu
Kierownik: prof. dr hab. Alicja Kędzia


kidney, renal cancer, interferon alpha, interleukin-2, immunochemotherapy


Paper presents the case of 51-year old man, who underwent nephrectomy due to the pT3N0M0 renal cell carcinoma of right kidney. Relapse - dissemination to liver and subsequently to lungs, occurred 8 months post surgery. An attempt of immunochemotherapy consisting of interleukin-2, interferon alpha and vinblastin was undertaken. Therapy, lasting 12 months, initially reflected in the partial regression of lesions, and subsequently - with the stabilization of disease persisting till the end of treatment. At present, more than a year post therapy, the patient is stable and free from any symptoms of cancer progression.


  1. Atzpodien J, Kirchner H, Hanninen EL et al: Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993; 29A, Suppl. 5; S6-8.
  2. Pectasides D, Varthalitis J, Kostopoulou M et al: An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer. Oncology 1998; 55; 10-15.
  3. Dutcher JP, Logan T, Gordon M et al: Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study. Clin Cancer Res 2000; 6; 3442-3450.
  4. Negrier S, Caty A, Lesimple T et al: Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. J Clin Oncol 2000; 18; 4009-4015.
  5. Vogelzang NJ, Lipton A, Figlin RA: Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial. J Clin Oncol 1993; 11; 1809-1816.
  6. Atzpodien J, Kirchner H, Illiger HJ et al: Il-2 in combination with INF alpha and 5-Fu versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001; 85; 1130-1136.
  7. Atzpodien J, Kirchner H, Jonas U et al: Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22; 1188-1194.
  8. Yagoda A, Abi-Rached B, Petrylak D: Chemotherapy for advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995; 22; 42-60.
  9. Hrushesky WJ, Murphy GP. Current status of the therapy of advanced renal carcinoma. J Surg Oncol 1977; 9; 277-288.
  10. Tourani JM, Pfister C, Tubiana N et al: Subcutaneous Administration Propeukin Program Cooperative Group: Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design ? the Subcutaneous Administration Propeukin Program Cooperative Group. J Clin Oncol 2003; 21; 3987-3994.
  11. O?Brien MF, Rea D, Rogers E et al: Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience. Eur Urol 2004; 45; 613-618.
  12. Mani S, Todd MB, Katz K, Poo WJ: Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers. J Urol 1995; 154; 35-40.
  13. Padrik P: Prognostic factors of immunotherapy in metastatic renal cell carcinoma. Med Oncol 2003; 20; 325-334.
  14. Kłaniewski T, Świątoniowski G, Suder E et al: Paliatywne leczenie rozsianego raka nerki z uwzględnieniem immunochemioterapii złożonej z interleukiny-2, interferonu alfa i winblastyny. Doniesienie wstępne. Onkol Pol 2003; 6; 21-24.
  15. Plasse T, Goss T, Dutcher J: Qality of life (QOL) assessment of renal cancer patients (PTS) treated with interleukin-2, interferon alpha and 5-Fluorouracil. Proc Annu Meet Am Soc Clin Oncol 1998; 17; A260.
  16. Fumagalli LA, Vinke J, Hoff W et al: Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy. J Immunother 2003; 26; 394-402.
  17. Motzer RJ, Mazumdar M, Bacik J et al: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17; 2530-2540.


Grzegorz Świątoniowski
Klinika Chorób Wewnętrznych
ul. Weigla 5
50-981 Wrocław
tel. (071) 366 05 17